B-hPD-L1 mice
C57BL/6-Cd274tm1(CD274)Bcgen/Bcgen • 110015

B-hPD-L1 mice

Catalog Number
110015
Strain Name
C57BL/6-Cd274tm1(CD274)Bcgen/Bcgen
Strain Background
C57BL/6
NCBI gene ID
29126 (Human)
Aliases
ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1

このページで

  • Description
  • Phenotypic analysis
  • Efficacy

ポスター

すべて表示

    出版物

      Description
      • Programmed Death-Ligand 1 (PD-L1): An immune checkpoint ligandthat contributes to tumor immune evasion through interaction with PD-1.
      • Gene Information: CD274 encodes a type I transmembrane protein ofthe B7 immune checkpoint family. The gene is localized at chromosome9p24.1.
      • Protein Expression: PD-L1 can be expressed on tumor cells and immunecells, including dendritic cells and macrophages, as well as vascularendothelial cells. Its expression can be upregulated by inflammatorysignals, particularly IFN-γ, in the tumor micro-environment.
      • Signaling Pathway: PD-L1 transmits inhibitory signals by binding to PD-1 on T cells, thereby suppressing T cell receptor signaling and anti-tumorimmune responses. This interaction constitutes a classic immuneevasion mechanism exploited by tumors. PD-L1 can also bind to B7-1(CD80) on T cells and dendritic cells, further modulating immuneactivation.
      • Therapeutic Targeting: Therapeutic strategies targeting the PD-1/PD-L1axis include monoclonal antibodies (e.g., anti-PD-1 and anti-PD-L1antibodies), which can reinvigorate antitumor T-cell responses byblocking immune checkpoint signaling.
      Human PD-L1 mRNA Expression Analysis in PD-L1 Humanized Mice
      • Mouse Pdl1  mRNA was detectable only in wild-type C57BL/6JNifdc mice.
      • Human PD-L1  mRNA was exclusively detectable in homozygous PD-L1 humanized mice, but not in wild-type C57BL/6JNifdc mice.

      Strain specific analysis of PD-L1  mRNA expression in wild-type C57BL/6JNifdc mice and homozygous PD-L1 humanized mice by RT-PCR. Mouse Pdl1  mRNA wasdetectable only in wild-type C57BL/6JNifdc mice (+/+). Human PD-L1  mRNA was detectable only in homozygous B-hPD-L1 mice (H/H), but not in wild-typeC57BL/6JNifdc mice.

      Human PD-L1 Protein Expression Analysis in Splenocytes of PD-L1 Humanized Mice
      • Human PD-L1 was detected on splenocytes only in homozygous PD-L1 humanized mice, but not in wild-type C57BL/6JNifdc mice.

      Strain specific PD-L1 expression analysis in homozygous PD-L1 humanized mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-L1 (H/H) mice stimulated with anti-CD3ε in vivo and analyzed by flow cytometry with species-specific anti-PD-L1 antibody. Mouse PD-L1 was only detectable in WT mice. Human PD-L1 was exclusively detectable in homozygous B-hPD-L1 but not in WT mice.

      Functional Assay-Analysis of Anti-PD-L1 Antibody Binding to MC38 and MC38-hPD-L1 Cells
      • Atezolizumab and avelumab bind to MC38 cells, while durvalumab can not bind to MC38 cells. 
      • Atezolizumab, avelumab and durvalumab can bind to MC38-hPD-L1 cells.

      Anti-hPD-L1 antibodies bind to MC38 and MC38-hPD-L1 cells. MC38 and MC38-hPD-L1 cells were collected and incubated with different antibodies. Flowcytometry analysis showed that atezolizumab and avelumab bind to MC38 cells, while durvalumab can not bind to MC38 cells. Atezolizumab, avelumab anddurvalumab can bind to MC38-hPD-L1 cells. *The antibodies were synthesized in-house.

      In Vivo Efficacy of Anti-human PD-L1 Antibody in PD-L1 Humanized Mice
      • Anti human PD-L1 antibody atezolizumab inhibited MC38-hPD-L1 tumor growth in PD-L1 humanized mice.
      • The PD-L1 humanized mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-L1 antibodies.

      Antitumor activity of anti-human PD-L1 antibody in PD-L1 humanized mice. (A) Anti-human PD-L1 antibody atezolizumab inhibited MC38-hPD-L1 tumor growth in B-hPD-L1 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-L1 mice (female, 6-week-old, n=5). Mice weregrouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human PD-L1 antibody with doses and schedules indicatedin panel. (B) Body weight changes during treatment. As shown in panel A, anti-human PD-L1 antibody was efficacious in controlling tumor growth in B-hPD-L1 mice,demonstrating that the B-hPD-L1 mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-L1 antibodies. Values are expressed as mean ±SEM.

      • Anti human PD-L1 antibody tecentriq inhibited MC38-hPD-L1 tumor growth in PD-L1 humanized mice.
      • The PD-L1 humanized mice  provide a powerful preclinical model for in vivo evaluation of anti-human PD-L1 antibodies.

      Antitumor activity of anti-human PD-L1 antibody in PD-L1 humanized mice. (A) Anti-human PD-L1 antibody tecentriq inhibited MC38-hPD-L1 tumor growth in B-hPD-L1mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-L1 mice (n=8). Mice were grouped when tumorvolume reached approximately 100 mm3, at which time they were treated with anti-human PD-L1 antibody with doses and schedules indicated in panel A. (B) Bodyweight changes during treatment. As shown in panel A, anti-human PD-L1 antibody was efficacious in controlling tumor growth in B-hPD-L1 mice, demonstratingthat the B-hPD-L1 mice provide a powerful preclinical model for in vivo efficacy evaluation of anti-human PD-L1 antibodies. Values are expressed as mean ± SEM.

      • Anti human PD-L1 antibody durvalumab inhibited MC38-hPD-L1 tumor growth in  PD-L1 humanized mice.
      • The PD-L1 humanized mice. provide a powerful preclinical model for in vivo evaluation of anti-human PD-L1 antibodies.

      Antitumor activity of anti-human PD-L1 antibody in PD-L1 humanized mice. (A) Anti-human PD-L1 antibody durvalumab (in-house) inhibited MC38-hPD-L1 tumor growthin B-hPD-L1 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-L1 mice (female, 6-week-old, n=5). Micewere grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-human PD-L1 antibody with doses and schedulesindicated in panel. (B) Body weight changes during treatment. As shown in panel A, different doses of human PD-L1 antibody durvalumab (in-house) inhibited tumorgrowth in different levels, demonstrating that the B-hPD-L1 mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-L1 antibodies. Valuesare expressed as mean ± SEM.

      * When publishing results obtained using this animal model, please acknowledge the source as follows: The animal model [B-hPD-L1 mice] (Cat# 110015) was purchased from Biocytogen.